193 results on '"Lim, Tze Peng"'
Search Results
2. A rapid and efficient approach for quantifying metformin in human plasma using Ultra-High performance liquid chromatography with UV-Detection: Relevance in Non-Diabetes clinical studies
3. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population – A prospective, multi-center, observational study (BLAST 1)
4. Pharmacokinetics of levetiracetam in neurosurgical ICU patients
5. The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia
6. Chapter 56 - Regulatory considerations for new drugs and devices
7. In vitro Pharmacodynamics and PK/PD in Animals
8. Individualized antimicrobial therapy using antibiotic combination testing and therapeutic drug monitoring to treat carbapenem-resistant Acintobacter baumannii infection
9. A Rapid and Efficient Approach for Quantifying Metformin in Human Plasma Using Uv-Detection Coupled Ultra-High Performance Liquid Chromatography: Relevance in Non-Diabetes Clinical Studies
10. In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates
11. Molecular mechanisms of azole resistance in Candida bloodstream isolates
12. Isavuconazole dosing in Asian patients with invasive mould infections – is there a role for therapeutic drug monitoring?
13. List of contributors
14. LipidA-IDER to Explore the Global Lipid A Repertoire of Drug-Resistant Gram-Negative Bacteria
15. High-concentration polymyxin B infusion: is it safe to give?
16. Correction to: Candidemia in a major regional tertiary referral hospital – epidemiology, practice patterns and outcomes
17. Therapeutic drug monitoring is necessary for patients receiving posaconazole tablet
18. Increase in Chlorhexidine Minimal Inhibitory Concentration of Acinetobacter baumannii Clinical Isolates after Implementation of Advanced Source Control
19. Antibacterial and antifouling catheter coatings using surface grafted PEG-b-cationic polycarbonate diblock copolymers
20. Candidemia in a major regional tertiary referral hospital – epidemiology, practice patterns and outcomes
21. Predictors and Outcomes of Healthcare-Associated Infections Caused by Carbapenem-Nonsusceptible Enterobacterales: A Parallel Matched Case-Control Study
22. Quantification of Fosfomycin in Combination with Nine Antibiotics in Human Plasma and Cation-Adjusted Mueller-Hinton II Broth via LCMS
23. In vitro Bactericidal Activities of Combination Antibiotic Therapies Against Carbapenem-Resistant Klebsiella pneumoniae With Different Carbapenemases and Sequence Types
24. Therapeutic drug monitoring is necessary for patients receiving posaconazole tablet
25. Optimizing hollow-fiber-based pharmacokinetic assay via chemical stability study to account for inaccurate simulated drug clearance of rifampicin
26. Pharmacokinetic/pharmacodynamic antimicrobial individualization and optimization strategies
27. Subtherapeutic posaconazole troughs despite high-dose posaconazole tablets in a patient with terminal ileum resection
28. Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures
29. Elimination of Extracellular Adenosine Triphosphate for the Rapid Prediction of Quantitative Plate Counts in 24 h Time-Kill Studies against Carbapenem-Resistant Gram-Negative Bacteria
30. In Vitro Pharmacodynamics of Fosfomycin against Carbapenem-Resistant Enterobacter cloacae and Klebsiella aerogenes
31. Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study
32. Determining the Development of Persisters in Extensively Drug-Resistant Acinetobacter baumannii upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry
33. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 °C
34. Rapid Antibiotic Combination Testing for Carbapenem-Resistant Gram-Negative Bacteria within Six Hours Using ATP Bioluminescence
35. Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections
36. Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections
37. Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae
38. Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model
39. mcr-1 in Multidrug-Resistant bla KPC-2 -Producing Clinical Enterobacteriaceae Isolates in Singapore
40. In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B
41. Antimicrobial Cluster Bombs: Silver Nanoclusters Packed with Daptomycin
42. From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB)
43. Physicochemical Stability Study of Polymyxin B in Various Infusion Solutions for Administration to Critically Ill Patients
44. Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections
45. Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot
46. Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections.
47. Multiple Genetic Mutations Associated with Polymyxin Resistance in Acinetobacter baumannii
48. Intravenous ceftaroline 200mg administered every 8h is safe and adequate for meticillin-resistant Staphylococcus aureus bloodstream infections in end-stage renal failure patients on haemodialysis: a case study
49. Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 Hours
50. In Vitro Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.